OCUL
OCULAR THERAPEUTIX, INC
NASDAQ · Healthcare · Biotechnology · US
$9.99
−1.48%Next report
Analyst consensus
- Next report date
- Nov 3, 2026
- EPS estimate
- -$0.36
- Revenue estimate
- $14.3M
Latest reported
- Last report date
- Aug 4, 2026
- EPS actual
- -$0.35
- EPS estimate
- -$0.40
- Revenue actual
- $13.5M
- Revenue estimate
- $13.2M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 2
- Avg surprise (4Q)
- -6.3%
- Revenue beats (12Q)
- 4
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $24
- PT range
- $23 – $25
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 4, 2026 | -$0.40 | -$0.35 | Beat 11.49% | $13.5M |
| May 5, 2026 | -$0.32 | -$0.41 | Miss -28.12% | $10.8M |
| Feb 5, 2026 | -$0.33 | -$0.29 | Beat 12.12% | $13.3M |
| Mar 3, 2025 | -$0.24 | -$0.29 | Miss -20.83% | $17.1M |
| Nov 14, 2024 | -$0.23 | -$0.26 | Miss -13.04% | $15.4M |
| Mar 11, 2024 | -$0.28 | -$0.28 | In line | $14.8M |
| Mar 6, 2023 | -$0.25 | -$0.24 | Beat 4.00% | $14.1M |
| Feb 28, 2022 | -$0.23 | -$0.23 | In line | $12.3M |
| May 5, 2021 | -$0.20 | -$0.24 | Miss -20.00% | $7.3M |
| Mar 11, 2021 | -$0.18 | -$0.23 | Miss -27.78% | $7.3M |
| Nov 5, 2020 | -$0.23 | -$0.17 | Beat 26.09% | $5.9M |
| Aug 7, 2020 | -$0.32 | -$0.34 | Miss -6.25% | $1.6M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 3, 2026